ProShares Ultra Nasdaq Biotechnology Rating → Trump’s Gift Could Unleash $51 Billion in New Wealth (From Wealthpin Pro) (Ad) Free BIB Stock Alerts $56.09 +0.48 (+0.86%) (As of 05/31/2024 ET) Add Compare Share Share RatingsStock AnalysisChartDividendHeadlinesHoldingsOptions ChainOwnershipRatingsShort InterestTrendsStock AnalysisChartDividendHeadlinesHoldingsOptions ChainOwnershipRatingsShort InterestTrends ProShares Ultra Nasdaq Biotechnology Aggregate Rating and Price Target (2024)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.BIB Aggregate RatingModerate Buy2.57Holdings in BIB have an aggregate rating of Moderate Buy based on 579 analyst ratings issued in the past year covering 43 companies (54.5% of the portfolio).BIB Aggregate Price Target$65.7217.17% UpsideHigh Prediction$86.82Average Prediction$65.72Low Prediction$47.25Holdings in BIB have an aggregate price target of $65.72 and a range of $47.25 to $86.82 covering 43 companies (54.5% of the portfolio).BIB Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy6 Buy rating(s)Moderate Buy28 Moderate Buy rating(s)Hold8 Hold rating(s)Reduce0 Reduce rating(s)Sell1 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by ProShares Ultra Nasdaq Biotechnology Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 43 BIB Holdings Export to ExcelWeightIn ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings6.28%AMGNAmgen$305.85+1.6%5 of 5 stars2.52$305.65 -0.1%21Short Interest ↑6.02%VRTXVertex Pharmaceuticals$455.34+2.8%4 of 5 stars2.50$438.62 -3.7%24Analyst ForecastInsider SellingNews CoverageHigh Trading Volume5.70%REGNRegeneron Pharmaceuticals$980.16+1.1%4 of 5 stars2.76$989.36 0.9%21Insider SellingNews CoverageHigh Trading Volume5.15%GILDGilead Sciences$64.27+0.3%5 of 5 stars2.35$83.69 30.2%17News CoverageGap DownHigh Trading Volume4.49%MRNAModerna$142.55-5.9%3 of 5 stars2.24$126.46 -11.3%17Insider Selling3.26%AZNAstraZeneca$78.02+1.6%3 of 5 stars2.67$88.00 12.8%9Analyst ForecastShort Interest ↓2.27%BIIBBiogen$224.94+2.2%5 of 5 stars2.65$286.50 27.4%26Analyst ForecastShort Interest ↑News Coverage1.35%ALNYAlnylam Pharmaceuticals$148.43-1.1%5 of 5 stars2.59$216.19 45.6%17Insider SellingHigh Trading Volume1.21%ILMNIllumina$104.28+3.2%5 of 5 stars2.30$164.65 57.9%20Short Interest ↑1.03%BMRNBioMarin Pharmaceutical$75.07+0.8%5 of 5 stars2.57$106.11 41.3%21Insider Selling1.00%NBIXNeurocrine Biosciences$135.41-0.9%5 of 5 stars2.80$150.85 11.4%25Analyst ForecastInsider SellingHigh Trading Volume0.96%SNYSanofi$49.03+2.5%3 of 5 stars2.40$55.00 12.2%5Short Interest ↓Analyst Revision0.93%UTHRUnited Therapeutics$275.13+1.7%5 of 5 stars2.90$309.44 12.5%10Insider SellingHigh Trading Volume0.92%INCYIncyte$57.79+0.9%5 of 5 stars2.44$73.69 27.5%18Short Interest ↓Positive NewsHigh Trading Volume0.90%VTRSViatris$10.60+1.1%1 of 5 stars1.33$11.00 3.8%3Insider Selling0.86%SRPTSarepta Therapeutics$129.86+4.3%5 of 5 stars2.80$164.00 26.3%15Analyst ForecastHigh Trading Volume0.86%MEDPMedpace$386.34+0.2%5 of 5 stars2.86$443.14 14.7%7Analyst ForecastInsider Selling0.86%RPRXRoyalty Pharma$27.41+3.9%5 of 5 stars3.00$46.75 70.6%4Positive NewsHigh Trading Volume0.80%ARGXargenx$371.02+2.4%3 of 5 stars2.71$520.68 40.3%21Analyst ForecastShort Interest ↓0.69%BNTXBioNTech$100.60+1.9%2 of 5 stars2.20$111.70 11.0%10Analyst ForecastShort Interest ↓0.63%ROIVRoivant Sciences$10.36-0.3%2 of 5 stars2.90$16.90 63.1%10Analyst ForecastAnalyst RevisionNews CoverageHigh Trading Volume0.54%PCVXVaxcyte$70.27+0.1%1 of 5 stars3.00$78.50 11.7%4Insider SellingPositive News0.53%ASNDAscendis Pharma A/S$135.10-1.7%3 of 5 stars2.89$179.44 32.8%9Analyst ForecastShort Interest ↓News Coverage0.46%BGNEBeiGene$148.85-3.5%3 of 5 stars2.80$251.93 69.3%10Short Interest ↓News CoveragePositive News0.46%ITCIIntra-Cellular Therapies$67.24+2.4%5 of 5 stars2.90$90.17 34.1%10Short Interest ↑0.46%JAZZJazz Pharmaceuticals$105.25-0.2%5 of 5 stars2.85$192.75 83.1%13Analyst UpgradeHigh Trading Volume0.45%RVMDRevolution Medicines$38.33+0.4%4 of 5 stars3.10$43.20 12.7%10Positive News0.45%BPMCBlueprint Medicines$105.56-0.8%1 of 5 stars2.53$103.94 -1.5%17News Coverage0.44%EXELExelixis$21.69+4.4%5 of 5 stars2.59$26.13 20.4%17Insider BuyingPositive NewsGap Up0.40%IONSIonis Pharmaceuticals$37.57+2.8%4 of 5 stars2.71$59.54 58.5%14Positive News0.40%HALOHalozyme Therapeutics$44.29+2.2%5 of 5 stars2.83$53.14 20.0%6Positive News0.36%CYTKCytokinetics$48.51-1.2%4 of 5 stars2.82$74.88 54.4%17Analyst Forecast0.35%BBIOBridgeBio Pharma$28.01-2.9%5 of 5 stars2.92$47.62 70.0%12Analyst ForecastAnalyst Revision0.34%APLSApellis Pharmaceuticals$39.25-3.7%4 of 5 stars2.81$74.38 89.5%16Analyst ForecastAnalyst Revision0.34%MDGLMadrigal Pharmaceuticals$236.16+4.7%5 of 5 stars2.73$345.09 46.1%11Positive News0.33%KRYSKrystal Biotech$160.05-1.0%4 of 5 stars3.00$177.63 11.0%9Positive News0.32%IBRXImmunityBio$6.42-2.9%0 of 5 stars2.00$6.00 -6.5%1Positive News0.32%CRSPCRISPR Therapeutics$53.74-0.6%2 of 5 stars2.31$73.46 36.7%16Short Interest ↑Analyst Revision0.30%IMVTImmunovant$25.39-3.9%3 of 5 stars3.00$49.00 93.0%17Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageHigh Trading Volume0.29%ALKSAlkermes$23.40+0.8%5 of 5 stars2.50$36.78 57.2%10High Trading Volume0.28%NUVLNuvalent$65.62-1.3%2 of 5 stars2.90$90.78 38.3%10Insider SellingPositive NewsHigh Trading Volume0.25%INSMInsmed$55.05-3.4%3 of 5 stars3.00$56.38 2.4%16Analyst ForecastInsider SellingShort Interest ↑Analyst RevisionNews Coverage0.25%AXSMAxsome Therapeutics$73.43-1.1%5 of 5 stars2.92$121.92 66.0%13Insider Selling This page (NASDAQ:BIB) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProShocking $16T Elon Musk Crypto LeakCrypto 101 MediaBiden replacement revealed?Paradigm PressWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsHow Biden has already won 2024Porter & CompanyThis unknown company solves the biggest issue with AIManward Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProShares Ultra Nasdaq Biotechnology Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
